Spectral launches sepsis test in Italy:
This article was originally published in Clinica
Spectral Diagnostics (Toronto, Canada) has begun selling its rapid sepsis testing system in Italy, through its existing local distributor, NGC Medical (Novedrate). The EAA (endotoxin activity assay) system is used to identify patients at risk of severe sepsis. Three systems have already been placed in major Italian hospitals. Spectral Diagnostics last week announced plans for a private placement to raise Can$5m (US$4m) to back launch activities for the system.